Copley Scientific Showcases Extensive Range of Tablet Testing Equipment at Analytica 2014
Copley Scientific will focus on systems from the company’s comprehensive range of test equipment for pharmaceutical solid dosage forms at Analytica 2014, which takes place from 1– 4 April 2014 in Munich, Germany. On show will be the Dissolution Tester DIS 8000, a rugged unit with eight stirred test vessels that is ideal for both R&D and routine QC applications. Like all Copley Scientific tablet dissolution testers it meets the latest specifications of the US, European and other pharmacopoeias.
With automation an increasing requirement, Copley Scientific’s Dissofract ‘Off-Line’ Dissolution Sampling System will be shown with the DIS 8000. The Dissofract is specifically designed to automatically remove samples from either six or eight dissolution vessels at predetermined times and deposit them in test tubes or HPLC vials for subsequent analysis. Dissofract delivers minimal cross contamination, short sampling times and supports the efficient and accurate assessment of dissolution profiles.
Copley Scientific is also a world-leading manufacturer of inhaler test equipment. Visitors to the stand at Analytica will be able to learn more about the market leading Next Generation Impactor (NGI) together with Abbreviated Impactor Measurement (AIM) inhaled testing tools, including the Fast Screening Impactor (FSI), and the Fast Screening Andersen (FSA).
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance